NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
Kathy L. de Graaf(Light Chain Bioscience (Switzerland)), Pietro Invernizzi(Azienda Ospedaliera San Gerardo), Stephen Ryder(Nottingham University Hospitals NHS Trust), Walter Ferlin(Light Chain Bioscience (Switzerland)), Marco Carbone(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Sulleman Moreea(National Health Service), Roger W. Chapman, Annarosa Floreani(University of Padua), Paul Richardson(University of Liverpool), C. Anne McCune(Bristol Royal Infirmary), David E.J. Jones(NIHR Newcastle Biomedical Research Centre), Cristina de Min(Therapeutics Clinical Research), David Adams(Bicêtre Hospital), G Lapeyre(Centre Hospitalier Universitaire de Bordeaux), Stuart M. Curbishley(University of Birmingham)
Cited by 48
Related Papers
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography
|Journal of the American Society of Echocardiography|2011|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k